ETF Prime: Murphy on the New Faces of the ETF Boom
Pfizer to buy cancer drug maker Trillium for $2.3B
Trillium Therapeutics Shares Increase Over 190% Pre-Market: Why It Happened
Trillium Therapeutics shares soar on Pfizer's $2.26B deal
Trillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billion